@article{c8b05fc23b95470896c65f5331911379,
title = "Early prediction of incident liver disease using conventional risk factors and gut-microbiome-augmented gradient boosting",
abstract = "The gut microbiome has shown promise as a predictive biomarker for various diseases. However, the potential of gut microbiota for prospective risk prediction of liver disease has not been assessed. Here, we utilized shallow shotgun metagenomic sequencing of a large population-based cohort (N > 7,000) with ∼15 years of follow-up in combination with machine learning to investigate the predictive capacity of gut microbial predictors individually and in conjunction with conventional risk factors for incident liver disease. Separately, conventional and microbial factors showed comparable predictive capacity. However, microbiome augmentation of conventional risk factors using machine learning significantly improved the performance. Similarly, disease-free survival analysis showed significantly improved stratification using microbiome-augmented models. Investigation of predictive microbial signatures revealed previously unknown taxa for liver disease, as well as those previously associated with hepatic function and disease. This study supports the potential clinical validity of gut metagenomic sequencing to complement conventional risk factors for prediction of liver diseases.",
keywords = "disease, gut, liver disease, metagenomics, microbiome, microbiota, prediction",
author = "Yang Liu and Guillaume M{\'e}ric and Havulinna, {Aki S.} and Teo, {Shu Mei} and Fredrik {\AA}berg and Matti Ruuskanen and Jon Sanders and Qiyun Zhu and Anupriya Tripathi and Karin Verspoor and Susan Cheng and Mohit Jain and Pekka Jousilahti and Yoshiki V{\'a}zquez-Baeza and Rohit Loomba and Leo Lahti and Teemu Niiranen and Veikko Salomaa and Rob Knight and Michael Inouye",
note = "Funding Information: V.S. was supported by the Finnish Foundation for Cardiovascular Research . M.I. was supported by the Munz Chair of Cardiovascular Prediction and Prevention . A.S.H. was supported by the Academy of Finland , grant no. 321356 . L.L. was supported by the Academy of Finland grant nos. 295741 and 307127 . T.N. was supported by the Emil Aaltonen Foundation , the Finnish Foundation for Cardiovascular Research , the Finnish Medical Foundation , and the Academy of Finland, grant no. 321351 . R.L. receives funding support from NIEHS ( 5P42ES010337 ), NCATS ( 5UL1TR001442 ), NIDDK ( U01DK061734 , R01DK106419 , P30DK120515 , R01DK121378 , and R01DK124318 ), and DOD PRCRP ( W81XWH-18-2-0026 ). This study was supported by the Victorian Government{\textquoteright}s Operational Infrastructure Support (OIS) program and by core funding from the British Heart Foundation ( RG/13/13/30194 ; RG/18/13/33946 ) and the NIHR Cambridge Biomedical Research Centre ( BRC-1215-20014 ). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. This work was supported by Health Data Research UK , which is funded by the UK Medical Research Council , Engineering and Physical Sciences Research Council , Economic and Social Research Council , Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates , Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation , and Wellcome . Funding Information: V.S. was supported by the Finnish Foundation for Cardiovascular Research. M.I. was supported by the Munz Chair of Cardiovascular Prediction and Prevention. A.S.H. was supported by the Academy of Finland, grant no. 321356. L.L. was supported by the Academy of Finland grant nos. 295741 and 307127. T.N. was supported by the Emil Aaltonen Foundation, the Finnish Foundation for Cardiovascular Research, the Finnish Medical Foundation, and the Academy of Finland, grant no. 321351. R.L. receives funding support from NIEHS (5P42ES010337), NCATS (5UL1TR001442), NIDDK (U01DK061734, R01DK106419, P30DK120515, R01DK121378, and R01DK124318), and DOD PRCRP (W81XWH-18-2-0026). This study was supported by the Victorian Government's Operational Infrastructure Support (OIS) program and by core funding from the British Heart Foundation (RG/13/13/30194; RG/18/13/33946) and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. This work was supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation, and Wellcome. Study design, Y.L. S.M.T. V.S. and M.I.; data analyses and interpretation, Y.L. G.M. A.S.H. M.R. and M.I.; investigation, Y.L. G.M. A.S.H. F.?. M.R. J.S. Q.Z. Y.V.-B. R.L. V.S. and M.I.; metagenomic sequencing analyses, J.S. Q.Z. A.T. Y.V.-B. and R.K.; supervision, S.M.T. K.V. S.C. M.J. P.J. R.L. L.L. T.N. V.S. R.K. and M.I.; all authors reviewed the manuscript and approved the final manuscript. V.S. has received honoraria for consulting from Novo Nordisk and Sanofi and travel support from Novo Nordisk. He also has ongoing research collaboration with Bayer Ltd (all unrelated to the present study). R.L. serves as a consultant or advisory board member for Anylam/Regeneron, Arrowhead Pharmaceuticals, Astra Zeneca, Bird Rock Bio, Boehringer Ingelheim, Bristol-Myer Squibb, Celgene, Cirius, CohBar, Conatus, Eli Lilly, Galmed, Gemphire, Gilead, Glympse Bio, GNI, GRI Bio, Inipharm, Intercept, Ionis, Janssen, Inc. Merck, Metacrine, Inc. NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Prometheus, Promethera, Sanofi, Siemens, and Viking Therapeutics. In addition, his institution has received grant support from Allergan, Boehringer Ingelheim, Bristol-Myers Squibb, Cirius, Eli Lilly and Company, Galectin Therapeutics, Galmed Pharmaceuticals, GE, Genfit, Gilead, Intercept, Grail, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, NuSirt, Pfizer, pH Pharma, Prometheus, and Siemens. He is also co-founder of Liponexus, Inc. Publisher Copyright: {\textcopyright} 2022 The Authors",
year = "2022",
month = may,
day = "3",
doi = "10.1016/j.cmet.2022.03.002",
language = "English (US)",
volume = "34",
pages = "719--730.e4",
journal = "Cell Metabolism",
issn = "1550-4131",
publisher = "Cell Press",
number = "5",
}